Close Menu

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals last week released data from a Phase II pilot study of its subcutaneously administered TTR-mediated amyloidosis (ATTR) drug revusiran, showing that the agent could knock down levels of its target protein by as much as 98.2 percent.

While treatment with revusiran, formerly known as ALN-TTRsc, was generally well tolerated, Alnylam disclosed that a number of patients in the open-label study experienced a variety of adverse events including one deemed serious.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.